JP2001503254A - 免疫刺激ポリヌクレオチド/免疫調節分子複合体 - Google Patents
免疫刺激ポリヌクレオチド/免疫調節分子複合体Info
- Publication number
- JP2001503254A JP2001503254A JP51864998A JP51864998A JP2001503254A JP 2001503254 A JP2001503254 A JP 2001503254A JP 51864998 A JP51864998 A JP 51864998A JP 51864998 A JP51864998 A JP 51864998A JP 2001503254 A JP2001503254 A JP 2001503254A
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- iss
- composition
- group
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6025—Nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.少なくとも1種の免疫刺激ヌクレオチド配列(ISS)を含むポリヌクレオチ ドに結合した免疫調節分子を含有する免疫調節組成物であって、前記分子が 抗原を含むものである、前記組成物。 2.抗原が、タンパク質、糖タンパク質、多糖類およびガングリオシドからなる 群から選択される、請求項1に記載の組成物。 3.ISSが、基CpG、p(GC)およびp(IC)から選択されるヌクレオチド配列を 含む、請求項2に記載の組成物。 4.ISSが、CG含有オリゴヌクレオチドを含む、請求項2に記載の組成物。 5.ISSが、さらに、pGヌクレオチド配列を含む、請求項4に記載の組成物。 6.CG含有オリゴヌクレオチドが、配列5'-プリン、プリン、CG、ピリミジ ン、ピリミジン-3'を有する、請求項4に記載の組成物。 7.CpG、p(GC)またはp(IC)含有ヌクレオチド配列が、パリンドローム2本鎖 または非パリンドローム1本鎖オリゴヌクレオチドである、請求項3に記載 の組成物。 8.オリゴヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、AG CGTC、GACGTC、GGCGTC、AACGCC、AGCGCC、GACGCC、GGCGCC、AACGCT、AGCGCT 、GACGCT、およびGGCGCTからなる群から選択される、請求項6に記載の組成 物。 9.オリゴヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、お よびAGCGTCからなる群から選択される、請求項6に記載の組成物。 10.オリゴヌクレオチド配列が、AACGTT、AGCGTT、およびGACGTTからなる群から 選択される、請求項6に記載の組成物。 11.ポリヌクレオチドが、さらに、直鎖状DNA配列を含む、請求項2に記載の 組成物。 12.ポリヌクレオチドが、さらに、環状DNA配列を含む、請求項2に記載の組 成物。 13.ポリヌクレオチドが、さらに、RNAヌクレオチド配列を含む、請求項2に 記載の組成物。 14.RNAヌクレオチド配列が、AACGUU、AACGpI、AACGpC、AGCGUC、AGCGpI、AG CGpC、GACGCU、GACGCpI、GACGCpC、GACGUU、GACGpI、GACGpC、GACGUC、GACG pI、GACGpCからなる群から選択される配列を含む、請求項13に記載の組成 物。 15.RNAヌクレオチド配列が、2本鎖ポリ(I・C)配列を含む、請求項13に記 載の組成物。 16.RNAヌクレオチド配列が、AACGUU、AACGpI、AACGpC、AGCGUC、AGCGpI、AG CGpCからなる群から選択される配列を含む、請求項13に記載の組成物。 17.RNAヌクレオチド配列が、AACGUU、AACGpI、AACGpCからなる群から選択さ れる配列を含む、請求項13に記載の組成物。 18.ボリヌクレオチドが、さらに、少なくとも1種の修飾オリゴヌクレオチドを 含む、請求項2に記載の組成物。 19.ISSが直鎖状DNA配列内に含まれ、さらに、ISSがプリン、プリン、 CG、ピリミジン、ピリミジンヌクレオチド配列を含む、請求項11に記載 の組成物。 20.ISSが直鎖状DNA配列内に含まれ、さらに、ISSがCG含有pGヌクレ オチド配列を含む、請求項11に記載の組成物。 21.ISSが環状DNAヌクレオチド配列内に含まれ、さらに、ISSがプリン 、プリン、CG、ピリミジン、ピリミジンヌクレオチド配列を含む、請求項 12に記載の組成物。 22.ISSが環状DNAヌクレオチド配列内に含まれ、さらに、ISSがCG含 有pGヌクレオチド配列を含む、請求項12に記載の組成物。 23.ISSがRNAヌクレオチド配列内に含まれ、さらに、ISSがプリン、プ リン、CG、ピリミジン、ピリミジンヌクレオチド配列を含む、請求項13 に記載の組成物。 24.ISSがRNAヌクレオチド配列内に含まれ、さらに、ISSがCG含有pG ヌク レオチド配列を含む、請求項13に記載の組成物。 25.CG含有ヌクレオチド配列が、さらに、修飾オリゴヌクレオチドを含む、請 求項4に記載の組成物。 26.5'-プリン、プリン、CG、ピリミジン、ピリミジン-3'ヌクレオチド配列が 、さらに、修飾オリゴヌクレオチドを含む、請求項6に記載の組成物。 27.少なくとも1種のISSを含むポリヌクレオチドに結合した免疫調節分子を 含有する免疫調節組成物であって、前記分子が抗原および免疫刺激ペプチド を含むものである、前記組成物。 28.ポリヌクレオチドがDNAまたはRNAである、請求項27に記載の組成物 。 29.免疫刺激ペプチドが、同時刺激性(co-stimulatory)分子、サイトカイン、ケ モカイン、ターゲティンタンパク質リガンド、およびトランス活性化因子か らなる群から選択される、請求項27に記載の組成物。 30.ISSが、基CG、p(GC)およびp(IC)から選択されるDNAまたはRNAヌ クレオチド配列を含む、請求項27に記載の組成物。 31.ISSが、CG含有オリゴヌクレオチドを含む、請求項27に記載の組成物 。 32.ISSが、さらに、pGヌクレオチド配列を含む、請求項31に記載の組成物 33.CG含有オリゴヌクレオチド配列が、ヌクレオチド配列5'-プリン、プリン 、CG、ピリミジン、ピリミジン-3'である、請求項31に記載の組成物。 34.CG含有ヌクレオチド配列が、パリンドローム2本鎖または非パリンドロー ム1本鎖オリゴヌクレオチドである、請求項31に記載の組成物。 35.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、AGCGTC、 GACGTC、GGCGTC、AACGCC、AGCGCC、GACGCC、GGCGCC、AACGCT、AGCGCT、GACG CT、およびGGCGCTからなる群から選択される、請求項33に記載の組成物。 36.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、およびAG CGTCからなる群から選択される、請求項33に記載の組成物。 37.ヌクレオチド配列が、AACGTT、AGCGTT、およびGACGTTからなる群から選択さ れる、請求項33に記載の組成物。 38.ポリヌクレオチドが、さらに、直鎖状DNAヌクレオチド配列を含む、請求 項29に記載の組成物。 39.ポリヌクレオチドが、さらに、環状DNAヌクレオチド配列を含む、請求項 29に記載の組成物。 40.ポリヌクレオチド部分が、さらに、RNAヌクレオチド配列を含む、請求項 29に記載の組成物。 41.RNAヌクレオチド配列が、AACGUU、AACGpI、AACGpC、AGCGUC、AGCGpI、AG CGpC、GACGCU、GACGCpI、GACGCpC、GACGUU、GACGpI、GACGpC、GACGUC、GACG pI、GACGpCからなる群から選択されるヌクレオチド配列を含む、請求項40 に記載の組成物。 42.RNAヌクレオチド配列が、2本鎖ポリ(I・C)ヌクレオチド配列を含む、請 求項40に記載の組成物。 43.RNAヌクレオチド配列が、AACGUU、AACGpI、AACGpC、AGCGUC、AGCGpI、AG CGpCからなる群から選択されるヌクレオチド配列を含む、請求項40に記載 の組成物。 44.RNAヌクレオチド配列が、AACGUU、AACGpI、AACGpCからなる群から選択さ れるヌクレオチド配列を含む、請求項40に記載の組成物。 45.ポリヌクレオチド部分が、さらに、少なくとも1種の修飾オリゴヌクレオチ ドを含む、請求項29に記載の組成物。 46.ISSが直鎖状DNAヌクレオチド配列内に含まれ、さらに、ISSがプリ ン、プリン、CG、ピリミジン、ピリミジンヌクレオチド配列を含む、請求 項38に記載の組成物。 47.ISSが直鎖状DNAヌクレオチド配列内に含まれ、さらに、ISSがCG 含有pGヌクレオチド配列を含む、請求項38に記載の組成物。 48.ISSが環状DNAヌクレオチド配列内に含まれ、さらに、ISSがプリン 、プリン、CG、ピリミジン、ピリミジンヌクレオチド配列を含む、請求項 39に記載の組成物。 49.ISSが環状DNAヌクレオチド配列内に含まれ、さらに、ISSがCG含 有pGヌクレオチド配列を含む、請求項39に記載の組成物。 50.ISSがRNAヌクレオチド配列内に含まれ、さらに、ISSがプリン、プ リン、CG、ピリミジン、ピリミジンヌクレオチド配列を含む、請求項40 に記載の組成物。 51.ISSがRNAヌクレオチド配列内に含まれ、さらに、ISSがCG含有pG ヌクレオチド配列を含む、請求項40に記載の組成物。 52.CG含有ヌクレオチド配列が、さらに、修飾オリゴヌクレオチドを含む、請 求項31に記載の組成物。 53.5'-プリン、プリン、CG、ピリミジン、ピリミジン-3'ヌクレオチド配列が 、さらに、修飾オリゴヌクレオチドを含む、請求項33に記載の組成物。 54.少なくとも1種のISSを含むポリヌクレオチドに結合した免疫調節分子を 含有する免疫調節組成物を投与することを含む免疫応答調節方法であって、 前記分子が抗原を含むものである、前記方法。 55.投与の経路が経皮経路である、請求項54に記載の方法。 56.投与の経路が低周波数超音波送達である、請求項54に記載の方法。 57.抗原が、タンパク質、糖タンパク質、多糖類およびガングリオシドからなる 群から選択される、請求項54に記載の方法。 58.ISSが、基CG、p(GC)およびp(IC)から選択されるDNAまたはRNAヌ クレオチド配列を含む、請求項57に記載の方法。 59.ISSが、CG含有オリゴヌクレオチドを含む、請求項57に記載の方法。 60.ISSが、さらに、pGヌクレオチド配列を含む、請求項59に記載の方法。 61.CG含有ヌクレオチド配列が、ヌクレオチド配列5'-プリン、プリン、CG 、ピリミジン、ピリミジン-3'である、請求項59に記載の方法。 62.CG含有ヌクレオチド配列が、パリンドロームまたは非パリンドロームオリ ゴヌクレオチドヌクレオチド配列である、請求項59に記載の方法。 63.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、AGCGTC、 GACGTC、GGCGTC、AACGCC、AGCGCC、GACGCC、GGCGCC、AACGCT、AGCGCT、GACG CT、およびGGCGCTからな る群から選択される、請求項59に記載の方法。 64.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、およびAG CGTCからなる群から選択される、請求項59に記載の方法。 65.ヌクレオチド配列が、AACGTT、AGCGTT、およびGACGTTからなる群から選択さ れる、請求項59に記載の方法。 66.免疫応答調節が、Th1応答の誘導を含む、請求項54に記載の方法。 67.抗原分子が、タンパク質、糖タンパク質、および多糖類からなる群から選択 される、請求項66に記載の方法。 68.ISSが、基CG、p(GC)およびp(IC)から選択されるDNAまたはRNAヌ クレオチド配列を含む、請求項67に記載の方法。 69.ISSが、CG含有オリゴヌクレオチドを含む、請求項67に記載の方法。 70.ISSが、さらに、pGヌクレオチド配列を含む、請求項69に記載の方法。 71.CG含有ヌクレオチド配列が、ヌクレオチド配列5'-プリン、プリン、CG 、ピリミジン、ピリミジン-3'である、請求項69に記載の方法。 72.CG含有ヌクレオチド配列が、2本鎖パリンドロームまたは1本鎖非パリン ドロームオリゴヌクレオチドヌクレオチド配列である、請求項69に記載の 方法。 73.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、AGCGTC、 GACGTC、GGCGTC、AACGCC、AGCGCC、GACGCC、GGCGCC、AACGCT、AGCGCT、GACG CT、およびGGCGCTからなる群から選択される、請求項69に記載の方法。 74.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、およびAG CGTCからなる群から選択される、請求項69に記載の方法。 75.ヌクレオチド配列が、AACGTT、AGCGTT、およびGACGTTからなる群から選択さ れる、請求項69に記載の方法。 76.少なくとも1種のISSを含むポリヌクレオチドに結合した免疫調節分子を 含有する免疫調節組成物を投与することを含む免疫応答調節方法であって、 前 記分子が抗原および免疫刺激ペプチドを含むものである、前記方法。 77.投与の経路が経皮経路である、請求項76に記載の方法。 78.投与の経路が低周波数超音波送達である、請求項76に記載の方法。 79.免疫刺激ペプチドが、同時刺激性分子、サイトカイン、ケモカイン、ターゲ ティンタンパク質リガンド、およびトランス活性化因子からなる群から選択 される、請求項76に記載の方法。 80.ISSが、基CG、p(GC)およびp(IC)から選択されるヌクレオチド配列を含 む、請求項79に記載の方法。 81.ISSが、CG含有オリゴヌクレオチドを含む、請求項79に記載の方法。 82.ISSが、さらに、pGヌクレオチド配列を含む、請求項81に記載の方法。 83.CG含有ヌクレオチド配列が、ヌクレオチド配列5'-プリン、プリン、CG 、ピリミジン、ピリミジン-3'である、請求項81に記載の方法。 84.CG含有ヌクレオチド配列が、2本鎖パリンドロームまたは1本鎖非パリン ドロームオリゴヌクレオチドヌクレオチド配列である、請求項81に記載の 方法。 85.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、AGCGTC、 GACGTC、GGCGTC、AACGCC、AGCGCC、GACGCC、GGCGCC、AACGCT、AGCGCT、GACG CT、およびGGCGCTからなる群から選択される、請求項81に記載の方法。 86.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、およびAG CGTCからなる群から選択される、請求項81に記載の方法。 87.ヌクレオチド配列が、AACGTT、AGCGTT、およびGACGTTからなる群から選択さ れる、請求項81に記載の方法。 88.免疫応答調節が、Th1応答の誘導を含む、請求項76に記載の方法。 89.抗原が、タンパク質、糖タンパク質、および多糖類からなる群から選択され る、請求項88に記載の方法。 90.ISSが、基CG、p(GC)およびp(IC)から選択されるヌクレオチド配列を含 む、請求項89に記載の方法。 91.ISSが、CG含有オリゴヌクレオチドを含む、請求項89に記載の方法。 92.ISSが、さらに、pGヌクレオチド配列を含む、請求項91に記載の方法。 93.CG含有ヌクレオチド配列が、ヌクレオチド配列5'-プリン、プリン、CG 、ピリミジン、ピリミジン-3'である、請求項91に記載の方法。 94.CG含有ヌクレオチド配列が、2本鎖パリンドロームまたは1本鎖非パリン ドロームオリゴヌクレオチドヌクレオチド配列である、請求項91に記載の 方法。 95.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、AGCGTC、 GACGTC、GGCGTC、AACGCC、AGCGCC、GACGCC、GGCGCC、AACGCT、AGCGCT、GACG CT、およびGGCGCTからなる群から選択される、請求項91に記載の方法。 96.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、およびAG CGTCからなる群から選択される、請求項91に記載の方法。 97.ヌクレオチド配列が、AACGTT、AGCGTT、およびGACGTTからなる群から選択さ れる、請求項91に記載の方法。 98.哺乳動物宿主に、免疫調節分子に結合したポリヌクレオチドを投与すること を含む、哺乳動物免疫系のクラスIMHCプロセシング経路に可溶性抗原を 導入して抗原に対するCTL応答を惹起する方法であって、前記分子が抗原 を含むものである、前記方法。 99.ポリヌクレオチドが少なくとも1種のISSを含む、請求項98に記載の方 法。 100.ポリヌクレオチドがISSを含まない、請求項98に記載の方法。 101.抗原が、タンパク質、糖タンパク質および多糖類からなる群から選択され る、請求項98に記載の方法。 102.ISSが、基CG、p(GC)およびp(IC)から選択されるヌクレオチド配列を 含む、請求項98に記載の方法。 103.ISSが、CG含有オリゴヌクレオチドを含む、請求項98に記載の方法 。 104.ISSが、さらに、pGヌクレオチド配列を含む、請求項103に記載の方 法 。 105.CG含有ヌクレオチド配列が、ヌクレオチド配列5'-プリン、プリン、CG 、ピリミジン、ピリミジン-3'である、請求項103に記載の方法。 106.CG含有ヌクレオチド配列が、2本鎖パリンドロームまたは1本鎖非パリ ンドロームオリゴヌクレオチドヌクレオチド配列である、請求項103に記 載の方法。 107.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、AGCGTC 、GACGTC、GGCGTC、AACGCC、AGCGCC、GACGCC、GGCGCC、AACGCT、AGCGCT、GA CGCT、およびGGCGCTからなる群から選択される、請求項102に記載の方法 。 108.ヌクレオチド配列が、AACGTT、AGCGTT、GACGTT、GGCGTT、AACGTC、およびA GCGTCからなる群から選択される、請求項102に記載の方法。 109.ヌクレオチド配列が、AACGTT、AGCGTT、およびGACGTTからなる群から選択 される、請求項102に記載の方法。 110.ポリヌクレオチドがGpGオリゴヌクレオチドを含む、請求項98に記載 の方法。 111.ヌクレオチド配列が、AAGGTT、AGGGTT、GAGGTT、GGGGTT、AAGGTC、AGGGTC 、GAGGTC、GGGGTC、AAGGCC、AGGGCC、GAGGCC、GGGGCC、AAGGCT、AGGGCT、GA GGCT、およびGGGGCTからなる群から選択される、請求項110に記載の方法 。 112.ヌクレオチド配列が、AAGGTT、AGGGTT、GAGGTT、GGGGTT、AAGGTC、およびA GGGTCからなる群から選択される、請求項110に記載の方法。 113.ヌクレオチド配列が、AAGGTT、AGGGTT、およびGAGGTTからなる群から選択 される、請求項110に記載の方法。 114.免疫調節分子に結合したポリヌクレオチドを含有する、哺乳動物免疫系の クラスIMHCプロセシング経路に可溶性抗原を導入して抗原に対するCT L応答を惹起するための組成物であって、前記分子が抗原を含むものである 、前記組成物。 115.抗原が、タンパク質、糖タンパク質および多糖類からなる群から選択され る、請求項114に記載の組成物。 116.ポリヌクレオチドが、GpGオリゴヌクレオチドを含む、請求項114に記 載の組成物。 117.ヌクレオチド配列が、AAGGTT、AGGGTT、GAGGTT、GGGGTT、AAGGTC、AGGGTC 、GAGGTC、GGGGTC、AAGGCC、AGGGCC、GAGGCC、GGGGCC、AAGGCT、AGGGCT、GA AGGGCT、GGGCT、およびGGGGCTからなる群から選択される、請求項116に 記載の組成物。 118.ヌクレオチド配列が、AAGGTT、AGGGTT、GAGGTT、GGGGTT、AAGGTC、およびA GGGTCからなる群から選択される、請求項116に記載の組成物。 119.ヌクレオチド配列が、AAGGTT、AGGGTT、およびGAGGTTからなる群から選択 される、請求項116に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2811896P | 1996-10-11 | 1996-10-11 | |
US60/028,118 | 1996-10-11 | ||
PCT/US1997/019004 WO1998016247A1 (en) | 1996-10-11 | 1997-10-09 | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001503254A true JP2001503254A (ja) | 2001-03-13 |
JP2001503254A5 JP2001503254A5 (ja) | 2005-06-16 |
JP4111403B2 JP4111403B2 (ja) | 2008-07-02 |
Family
ID=21841670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51864998A Expired - Lifetime JP4111403B2 (ja) | 1996-10-11 | 1997-10-09 | 免疫刺激ポリヌクレオチド/免疫調節分子複合体 |
Country Status (9)
Country | Link |
---|---|
US (3) | US6610661B1 (ja) |
EP (2) | EP1537877A3 (ja) |
JP (1) | JP4111403B2 (ja) |
AT (1) | ATE292980T1 (ja) |
AU (1) | AU4992197A (ja) |
CA (1) | CA2268825C (ja) |
DE (1) | DE69733020T2 (ja) |
ES (1) | ES2241042T3 (ja) |
WO (1) | WO1998016247A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004100965A1 (ja) * | 2003-05-15 | 2004-11-25 | Japan Science And Technology Agency | 免疫刺激剤 |
JP2006507265A (ja) * | 2002-08-15 | 2006-03-02 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫刺激性組成物、および免疫応答の刺激方法 |
WO2010098432A1 (ja) | 2009-02-27 | 2010-09-02 | 東レ株式会社 | 免疫原性組成物 |
WO2012026508A1 (ja) | 2010-08-26 | 2012-03-01 | 東レ株式会社 | 免疫原性組成物 |
WO2015118789A1 (ja) * | 2014-02-06 | 2015-08-13 | 独立行政法人科学技術振興機構 | ペプチド/β-1,3-グルカン複合体及びその製造方法並びにそれを含む医薬組成物 |
Families Citing this family (311)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US20030109469A1 (en) * | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
DE69737413T2 (de) | 1996-01-04 | 2007-10-31 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Bakterioferritin aus helicobacter pylori |
WO1997028259A1 (en) * | 1996-01-30 | 1997-08-07 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
JP2000507225A (ja) * | 1996-03-08 | 2000-06-13 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | mab 3E10 ならびにその突然変異体および/または機能性フラグメントを使用する送達システム |
JP4111403B2 (ja) | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 免疫刺激ポリヌクレオチド/免疫調節分子複合体 |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
ES2333069T3 (es) * | 1997-03-10 | 2010-02-16 | Ottawa Hospital Research Institute | Uso de acidos nucleicos que contienen dinucleotido cpg no metilado en combinacion con alumbre como adyuvante. |
AU753172B2 (en) * | 1997-06-06 | 2002-10-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1374894A3 (en) * | 1997-06-06 | 2004-09-22 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1872786A1 (en) * | 1997-09-05 | 2008-01-02 | The Regents of the University of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
CA2323929C (en) * | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
EP1078053B1 (en) * | 1998-05-14 | 2005-09-28 | Coley Pharmaceutical GmbH | METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
DK1077722T3 (da) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
WO1999066947A1 (en) | 1998-06-23 | 1999-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant therapy |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
AU776288B2 (en) * | 1998-10-05 | 2004-09-02 | Regents Of The University Of California, The | Methods and adjuvants for stimulating mucosal immunity |
AU6425999A (en) * | 1998-10-09 | 2000-05-01 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
DK2204186T3 (en) | 1999-02-17 | 2016-07-18 | Csl Ltd | Immunogenic complexes, and related methods |
JP4812942B2 (ja) | 1999-02-26 | 2011-11-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | CGモチーフを含むオリゴヌクレオチドを用いるNeisseria抗原殺菌活性の増強 |
ES2242604T3 (es) | 1999-02-26 | 2005-11-16 | Chiron Corporation | Microemulsiones con macroparticulas y microparticulas adsorbidas. |
WO2000061151A2 (en) | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
IL145982A0 (en) | 1999-04-19 | 2002-07-25 | Smithkline Beecham Biolog | Vaccines |
US6737066B1 (en) * | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
US7479285B1 (en) | 1999-08-19 | 2009-01-20 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US8017590B1 (en) | 1999-10-22 | 2011-09-13 | Sanofi Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
US8017742B2 (en) * | 1999-11-10 | 2011-09-13 | Japan Science And Technology Agency | Gene carrier |
US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
DE60131430T2 (de) * | 2000-01-14 | 2008-10-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
US20010044416A1 (en) * | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
AT409085B (de) * | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
AU2001249609A1 (en) | 2000-03-28 | 2001-10-08 | Department Of Veterans Affairs | Methods for increasing a cytotoxic T lymphocyte response in vivo |
EP1282702B1 (en) | 2000-05-10 | 2006-11-29 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
US8568742B2 (en) * | 2000-06-08 | 2013-10-29 | Valneva Austria Gmbh | Methods and compositions involving immunostimulatory oligodeoxynucleotides |
WO2002002172A1 (en) * | 2000-06-30 | 2002-01-10 | Univ Jefferson | Dna palindrome - oligoguanylic acid compositions and uses thereof |
KR100917101B1 (ko) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | 플렉시블 금속적층체 및 그 제조방법 |
US6787524B2 (en) * | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
PL211151B1 (pl) | 2000-10-18 | 2012-04-30 | Glaxosmithkline Biolog Sa | Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu |
EP2284183A1 (en) | 2000-10-27 | 2011-02-16 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A and B |
NZ526322A (en) | 2000-12-27 | 2005-06-24 | Dynavax Tech Corp | Immunomodulatory polynucleotides and methods of using the same |
FR2823222B1 (fr) | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
DE60141773D1 (de) * | 2001-04-20 | 2010-05-20 | Inst Systems Biology | Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren |
US8703146B2 (en) * | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
US7858588B2 (en) | 2001-05-21 | 2010-12-28 | Intercell Ag | Immunostimulatory oligodeoxynucleic molecules |
ATE490267T1 (de) * | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
DK2423335T3 (da) | 2001-06-21 | 2014-08-18 | Dynavax Tech Corp | Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
US20030148316A1 (en) * | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
JP4607452B2 (ja) | 2001-08-07 | 2011-01-05 | ダイナバックス テクノロジーズ コーポレイション | 免疫調節性組成物、製剤およびその使用方法 |
WO2003020884A2 (en) | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
CN1604795B (zh) | 2001-08-17 | 2010-05-26 | 科勒制药股份公司 | 具有提高的活性的组合基序免疫刺激寡肽 |
CN1599623B (zh) | 2001-09-14 | 2011-05-11 | 赛托斯生物技术公司 | 免疫刺激物向病毒样颗粒内的包装:制备方法与用途 |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
US7615227B2 (en) | 2001-12-20 | 2009-11-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce angiogenesis |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
ES2607431T3 (es) | 2002-02-20 | 2017-03-31 | Glaxosmithkline Biologicals Sa | Micropartículas con moléculas que contienen polipéptidos adsorbidos |
US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AU2003254585A1 (en) | 2002-07-24 | 2004-02-16 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
EP1551376A4 (en) * | 2002-08-12 | 2010-10-06 | Dynavax Tech Corp | IMMUNOMODULATORY COMPOSITIONS, THEIR METHODS OF PREPARATION AND USE |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
EP1537418A2 (en) | 2002-09-13 | 2005-06-08 | Intercell AG | Method for isolating hepatitis c virus peptides |
US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
EP1545575A4 (en) | 2002-09-19 | 2006-04-05 | Us Gov Health & Human Serv | POLYPEPTIDES OF P. ARIASI POLYPEPTIDES P. PERNICIOSUS AND METHODS OF USE |
US7179797B2 (en) * | 2002-09-27 | 2007-02-20 | Wisconsin Alumni Research Foundation | Methods and compositions for treating prostate cancer using DNA vaccines |
WO2004037189A2 (en) | 2002-10-23 | 2004-05-06 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
BR0315872A (pt) | 2002-10-29 | 2006-07-18 | Us Gov Health & Human Serv | Polipeptìdeos de lutzomyia longipalpis e processos de utilização e método de uso |
ATE544466T1 (de) | 2002-10-29 | 2012-02-15 | Coley Pharm Group Inc | Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion |
WO2004098491A2 (en) * | 2002-11-01 | 2004-11-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES |
EP1562982B1 (en) | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics S.r.l. | Unexpected surface proteins in neisseria meningitidis |
CN101955976A (zh) * | 2002-11-21 | 2011-01-26 | 贝希尔治疗学股份有限公司 | 预防和治疗疾病的方法及免疫调节核酸组合物 |
US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
US7354593B2 (en) | 2002-12-09 | 2008-04-08 | Merial Limited | Coccidial vaccine and methods of making and using same |
WO2004053104A2 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
SI1575977T1 (sl) | 2002-12-23 | 2010-01-29 | Dynavax Tech Corp | Imunostimulirni sekvenčni polinukleotidi in postopki za njihovo uporabo |
US7625872B2 (en) | 2002-12-23 | 2009-12-01 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
WO2004060396A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
EP1594524B1 (en) | 2003-01-21 | 2012-08-15 | Novartis Vaccines and Diagnostics, Inc. | Use of tryptanthrin compounds for immune potentiation |
AU2004224746B2 (en) | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
CA2521050A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
CA2528007C (en) | 2003-06-02 | 2012-03-27 | Chiron Corporation | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
EP1663316A2 (en) | 2003-09-25 | 2006-06-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid lipophilic conjugates |
GB0323968D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
US8188254B2 (en) * | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
ES2417019T3 (es) | 2003-11-13 | 2013-08-05 | University Of Georgia Research Foundation, Inc. | Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa |
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
US20050175630A1 (en) * | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
ES2374549T3 (es) | 2004-01-21 | 2012-02-17 | Merial Limited | Vacunas de fcv inactivadas mejoradas. |
US7973016B2 (en) * | 2004-01-23 | 2011-07-05 | Joslin Diebetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
US7820175B2 (en) | 2004-03-19 | 2010-10-26 | Herbal Spring, Llc | Herbal therapy for the treatment of food allergy |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
CA2567789A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
WO2006002422A2 (en) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
US20060287263A1 (en) * | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing antigen-specific immune responses |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
US8759305B2 (en) | 2004-09-01 | 2014-06-24 | Dynavax Technologies Corporation | Methods and compositions for inhibition of innate immune responses and autoimmunity |
DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
US9573979B2 (en) | 2004-09-24 | 2017-02-21 | Susanne Modrow | Modified VP1-capsid protein of parvovirus B19 |
US7998733B2 (en) | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
CN101107007B (zh) | 2005-01-27 | 2011-08-17 | 奥克兰儿童医院及研究中心 | 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗 |
KR20070110901A (ko) * | 2005-03-04 | 2007-11-20 | 다이나박스 테크놀로지 코퍼레이션 | 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(iss)을 갖는올리고뉴클레오티드를 포함하는 백신 |
US8642577B2 (en) | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
ES2343270T3 (es) | 2005-04-25 | 2010-07-27 | Merial Ltd. | Vacunas contra el virus nipah. |
CN101273055B (zh) | 2005-04-29 | 2016-03-16 | 葛兰素史密丝克莱恩生物有限公司 | 用于预防或治疗结核分枝杆菌感染的新方法 |
GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
EP2380584B1 (en) | 2005-07-01 | 2013-10-16 | Index Pharmaceuticals AB | Immunostimulatory method |
PL2179737T3 (pl) | 2005-07-01 | 2014-01-31 | Index Pharmaceuticals Ab | Sposób do modulowania wrażliwości na steroidy |
BRPI0612408A2 (pt) * | 2005-07-07 | 2010-11-03 | Pfizer | terapia para tratamento de cáncer em combinação com anticorpo anti-ctla-4 e oligodesoxinucleotìdeo sintético contendo o motivo cpg |
US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
AU2006306805A1 (en) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
WO2007052058A1 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
US10842867B2 (en) | 2005-11-04 | 2020-11-24 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
KR20080100353A (ko) * | 2006-02-01 | 2008-11-17 | 더 존스 홉킨스 유니버시티 | 신생물성 또는 감염성 질환의 면역예방 또는 면역요법용 폴리펩티드-핵산 접합체 |
WO2007092315A2 (en) * | 2006-02-03 | 2007-08-16 | The Regents Of The University Of California | Immunostimulation by cpg oligonucleotide-virus complexes |
ES2526879T3 (es) * | 2006-02-15 | 2015-01-16 | Adiutide Pharmaceuticals Gmbh | Composiciones y procedimientos para formulaciones de oligonucleótidos |
US7455844B2 (en) | 2006-03-29 | 2008-11-25 | Merial Limited | Vaccine against streptococci |
US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
DK2032592T3 (da) | 2006-06-12 | 2013-09-02 | Cytos Biotechnology Ag | Fremgangsmåder til pakning af oligonukleotider til virus-lignende partikler af rna-bakteriofager |
EP2046954A2 (en) | 2006-07-31 | 2009-04-15 | Curevac GmbH | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
DE102006035618A1 (de) * | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
AU2007354917B2 (en) | 2006-09-26 | 2013-06-06 | Access To Advanced Health Institute | Vaccine composition containing synthetic adjuvant |
MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
US20090142362A1 (en) * | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
JP5714818B2 (ja) * | 2006-11-09 | 2015-05-07 | ダイナバックス テクノロジーズ コーポレイション | 免疫刺激性オリゴヌクレオチドを使用する長期疾患修飾 |
CN101611048B (zh) | 2006-12-12 | 2012-11-07 | 赛托斯生物技术公司 | 含有高浓度鸟嘌呤单体的寡核苷酸 |
CN101641010A (zh) | 2007-01-26 | 2010-02-03 | 路易斯维尔大学研究基金会公司 | 用作疫苗的外来体组分的修饰 |
LT2137210T (lt) | 2007-03-02 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Naujas būdas ir kompozicijos |
AU2008256644B2 (en) | 2007-05-24 | 2014-07-03 | The United States Government As Represented By The Department Of Veterans Affairs | Intranuclear protein transduction through a nucleoside salvage pathway |
CA2695385A1 (en) * | 2007-07-31 | 2009-02-05 | Atul Bedi | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
KR20100068390A (ko) | 2007-08-13 | 2010-06-23 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
WO2009026465A2 (en) * | 2007-08-21 | 2009-02-26 | Dynavax Technologies Corporation | Composition and methods of making and using influenza proteins |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
CA2703931C (en) | 2007-10-26 | 2016-08-16 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
ES2664753T3 (es) | 2007-12-07 | 2018-04-23 | Glaxosmithkline Biologicals Sa | Composiciones de inducción de respuestas inmunes |
SI2176408T1 (sl) | 2008-01-31 | 2015-05-29 | Curevac Gmbh | Nukleinske kisline, ki vsebujejo formulo (NuGiXmGnNv)a in njeni derivati kot imunostimulirajoča sredstva/adjuvanse |
AU2009223613B2 (en) | 2008-03-10 | 2014-09-25 | Children's Hospital & Research Center At Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
CA2724418A1 (en) | 2008-05-15 | 2009-11-19 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
WO2009143524A2 (en) | 2008-05-23 | 2009-11-26 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
US8580280B2 (en) | 2008-06-27 | 2013-11-12 | Zoetis Llc | Adjuvant compositions |
CN102223876A (zh) | 2008-09-26 | 2011-10-19 | 纳米生物公司 | 纳米乳剂治疗性组合物及其使用方法 |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
MY159543A (en) | 2008-11-28 | 2017-01-13 | Merial Inc | Recombinant avian influenza vaccine and uses thereof |
AU2009325950B2 (en) | 2008-12-09 | 2013-03-07 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
EA201500910A1 (ru) | 2009-02-10 | 2016-04-29 | Новартис Аг | Вакцины против гриппа со сниженным количеством сквалена |
CA2757030C (en) | 2009-04-03 | 2019-01-15 | Merial Limited | Vectors comprising newcastle disease viruses and compositions thereof |
CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
EP2442827B1 (en) | 2009-06-16 | 2016-01-06 | The Regents of the University of Michigan | Nanoemulsion vaccines |
RU2518291C2 (ru) | 2009-07-30 | 2014-06-10 | Пфайзер Вэксинс ЭлЭлСи | Антигенные tau-пептиды и их применения |
MX2012002114A (es) | 2009-08-21 | 2012-08-08 | Univ Georgia | Vacuna de paramixovirus aviar recombinante y metodo para hacerla y usarla. |
CA2771770A1 (en) | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
CA2785585A1 (en) | 2009-12-22 | 2011-06-30 | Celldex Therapeutics, Inc. | Vaccine compositions |
CN103260643A (zh) | 2009-12-28 | 2013-08-21 | 梅里亚有限公司 | 重组ndv抗原及其用途 |
EP2534150B1 (en) | 2010-02-12 | 2017-04-05 | Chimerix, Inc. | Methods of treating viral infection |
US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
CN103492410A (zh) | 2010-03-12 | 2014-01-01 | 梅里亚有限公司 | 蓝舌病毒重组疫苗和其使用 |
GB201005005D0 (en) | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
BR122021020829B8 (pt) | 2010-03-30 | 2022-12-27 | Children´S Hospital & Res Center At Oakland | Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada |
CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
US8658603B2 (en) | 2010-06-16 | 2014-02-25 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
AU2011268211B2 (en) | 2010-06-16 | 2015-07-16 | Dynavax Technologies Corporation | Methods of treatment using TLR7 and/or TLR9 inhibitors |
WO2012015979A2 (en) * | 2010-07-27 | 2012-02-02 | The Regents Of The University Of California | Hmgb1-derived peptides enhance immune response to antigens |
CN107648604A (zh) | 2010-07-30 | 2018-02-02 | 库瑞瓦格股份公司 | 聚合物载体运载物复合物及聚合物载体的用途 |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012030720A1 (en) | 2010-08-31 | 2012-03-08 | Merial Limited | Newcastle disease virus vectored herpesvirus vaccines |
CA2813466A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions |
US20120114688A1 (en) | 2010-11-08 | 2012-05-10 | Infectious Disease Research Institute | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
GB201106357D0 (en) | 2011-04-14 | 2011-06-01 | Pessi Antonello | Composition and uses thereof |
NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
US20120301479A1 (en) | 2011-05-27 | 2012-11-29 | Jean-Christophe Audonnet | Hendra virus recombinant compositions and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PE20141547A1 (es) | 2011-09-16 | 2014-10-25 | Ucb Pharma Sa | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile |
CN110511939A (zh) | 2011-10-03 | 2019-11-29 | 现代泰克斯公司 | 修饰的核苷、核苷酸和核酸及其用途 |
EP2596806A1 (en) | 2011-11-25 | 2013-05-29 | Index Pharmaceuticals AB | Method for prevention of colectomy |
ES2719409T5 (es) | 2011-11-30 | 2022-12-07 | Boehringer Ingelheim Animal Health Usa Inc | Vectores recombinantes de Gallid herpesvirus 3 (mdv serotipo 2) que expresan antígenos de patógenos aviares y usos de los mismos |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
TR201908003T4 (tr) | 2012-02-07 | 2019-06-21 | Infectious Disease Res Inst | TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları. |
CN104203274B (zh) | 2012-02-14 | 2017-09-08 | 梅里亚股份有限公司 | 轮状病毒亚单位疫苗及其制备和使用的方法 |
EP2833923A4 (en) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
EP2841098A4 (en) | 2012-04-23 | 2016-03-02 | Allertein Therapeutics Llc | NANOPARTICLES FOR THE TREATMENT OF ALLERGIES |
SI2850431T1 (en) | 2012-05-16 | 2018-08-31 | Immune Design Corp. | Vaccine against HSV-2 |
EP2666785A1 (en) | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
CA2876196C (en) | 2012-06-13 | 2021-09-21 | Merial Limited | Reassortant btv vaccines |
DK2866828T3 (en) | 2012-06-27 | 2018-01-15 | Merial Inc | IMPROVED STREPTOCOCCUS SUIS VACCINES AND METHODS OF PRODUCING AND USING THEREOF |
AU2013290597B2 (en) | 2012-07-17 | 2016-02-04 | Boehringer Ingelheim Animal Health USA Inc. | Attenuated swine influenza vaccines and methods of making and use thereof |
EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
MX358782B (es) | 2012-08-30 | 2018-09-04 | Merial Inc | Expresión de proteina ksac quimérica y método para producir proteínas solubles mediante alta presión. |
US9555098B2 (en) | 2012-09-10 | 2017-01-31 | Merial Inc. | Attenuated parvovirus vaccine for Muscovy duck parvovirus and goose parvovirus (Derzsys disease) |
ES2684556T3 (es) | 2012-11-08 | 2018-10-03 | Merial, Inc. | Vacunas de mannheimia haemolytica atenuadas y procedimientos de fabricación y uso |
PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
NZ709289A (en) | 2012-12-18 | 2016-09-30 | Asia Pacific Special Nutrients Sdn Bhd | High resolution melt genotyping of ndv strains |
BR112015018330A2 (pt) | 2013-02-01 | 2017-07-18 | Univ Auburn | cepas de flavobacterium vivas modificadas, vacinas estabilizadas compreendendo as mesmas, e métodos de preparo e uso das mesmas |
WO2014153087A1 (en) | 2013-03-14 | 2014-09-25 | President And Fellows Of Harvard College | Nanoparticle-based compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9909114B2 (en) | 2013-03-28 | 2018-03-06 | Infectious Disease Research Institute | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis |
MX2015013894A (es) | 2013-04-03 | 2015-12-11 | Allertein Therapeutics Llc | Composiciones de nanoparticulas novedosas. |
EA032326B1 (ru) | 2013-04-18 | 2019-05-31 | Иммьюн Дизайн Корп. | Монотерапия gla для применения в лечении рака |
US20210145963A9 (en) | 2013-05-15 | 2021-05-20 | The Governors Of The University Of Alberta | E1e2 hcv vaccines and methods of use |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
CA2915728A1 (en) | 2013-08-21 | 2015-02-26 | Thomas Kramps | Respiratory syncytial virus (rsv) vaccine |
UA121200C2 (uk) | 2013-09-19 | 2020-04-27 | Зоетіс Сервісіз Ллс | Ад'ювант на основі олії |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
US9757445B2 (en) | 2013-11-01 | 2017-09-12 | Merial Inc. | Attenuated Pasteurella multocida vaccines and methods of making and use thereof |
ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
WO2015063611A2 (en) | 2013-11-01 | 2015-05-07 | University Of Oslo | Albumin variants and uses thereof |
WO2015070207A2 (en) | 2013-11-11 | 2015-05-14 | The Government Of The United States, As Represented By The Secretary Of The Army | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same |
DK3069138T3 (en) | 2013-11-15 | 2019-04-08 | Univ Oslo Hf | CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF |
US20160287696A1 (en) | 2013-11-20 | 2016-10-06 | La Jolla Institute For Allergy And Immunology | Pan pollen immunogens and methods and uses for immune response modulation |
WO2015077442A2 (en) | 2013-11-20 | 2015-05-28 | La Jolla Institute For Allergy And Immunology | Grass pollen immunogens and methods and uses for immune response modulation |
WO2015092710A1 (en) | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
BR112016015422A2 (pt) | 2013-12-31 | 2017-10-24 | Infectious Disease Res Inst | formulações de vacina de frasco único |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
WO2015131053A1 (en) | 2014-02-28 | 2015-09-03 | Alk-Abelló A/S | Polypeptides derived from phl p and methods and uses thereof for immune response modulation |
EP3122374B1 (en) | 2014-03-25 | 2019-02-20 | Merial, Inc. | Immunological compositions containing attenuated histophilus somni |
CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
US9713639B2 (en) | 2014-05-19 | 2017-07-25 | Merial, Inc. | Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (PEDV) |
JP7158853B2 (ja) | 2014-10-10 | 2022-10-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物 |
KR102508719B1 (ko) | 2015-01-16 | 2023-03-09 | 조에티스 서비시즈 엘엘씨 | 구제역 백신 |
WO2016141320A2 (en) | 2015-03-05 | 2016-09-09 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
US9944904B2 (en) | 2015-05-14 | 2018-04-17 | Merial Inc. | Method for porcine circovirus production and PCV2 vaccines |
CN108025018B (zh) | 2015-05-29 | 2021-08-17 | 默沙东公司 | 用于治疗癌症的pd-1拮抗剂和cpg-c型寡核苷酸的组合产品 |
EP3889166A1 (en) | 2015-06-23 | 2021-10-06 | Boehringer Ingelheim Animal Health USA Inc. | Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof |
CN107949398A (zh) | 2015-06-26 | 2018-04-20 | 梅里亚股份有限公司 | 灭活的犬流感疫苗以及其制备方法和其用途 |
US10758605B2 (en) | 2015-06-29 | 2020-09-01 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating cancer and promoting wound healing |
KR20180041724A (ko) | 2015-08-20 | 2018-04-24 | 메리얼 인코포레이티드 | Fcv 재조합 백신 및 그의 용도 |
FI3355915T3 (fi) | 2015-09-29 | 2024-01-12 | Boehringer Ingelheim Animal Health Usa Inc | Koirien parvoviruksen (CPV) viruksen kaltaisten hiukkasten (VLP) rokotteet ja niiden käytöt |
RU2702835C1 (ru) | 2015-10-08 | 2019-10-11 | Мериал, Инк. | Живая ослабленная гетерологичная вакцина от leptospira |
US10780158B2 (en) | 2015-11-16 | 2020-09-22 | Georgia State University Research Foundation, Inc. | Tunable vaccine platform against pathogens of the paramyxovirus family |
RU2714428C2 (ru) | 2015-11-23 | 2020-02-14 | Мериал, Инк. | Слитые белки fmdv-e2 и их применение |
TWI760322B (zh) | 2016-01-29 | 2022-04-11 | 美商百靈佳殷格翰動物保健美國有限公司 | 重組腺病毒載體裝載之fmdv疫苗及其用途 |
WO2017158421A1 (en) | 2016-03-14 | 2017-09-21 | University Of Oslo | Anti-viral engineered immunoglobulins |
TN2018000301A1 (en) | 2016-03-14 | 2020-01-16 | Univ Oslo | Engineered immunoglobulins with altered fcrn binding |
WO2017176950A2 (en) | 2016-04-07 | 2017-10-12 | Merial, Inc. | Heartworm vaccine, methods and uses thereof |
BR112018071125A8 (pt) | 2016-04-14 | 2022-06-28 | Genzyme Corp | Composições múltiplas-doses contendo um conservante de poliamida antimicrobiana ou de octenidina . |
US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
WO2017221072A2 (en) | 2016-06-21 | 2017-12-28 | University Of Oslo | Hla binding vaccine moieties and uses thereof |
WO2018037045A1 (en) | 2016-08-23 | 2018-03-01 | Glaxosmithkline Biologicals Sa | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
MX2019003035A (es) | 2016-09-16 | 2019-09-13 | Infectious Disease Res Inst | Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra. |
BE1024774B1 (fr) | 2016-09-29 | 2018-07-02 | Glaxosmithkline Biologicals Sa | Compositions et procedes de traitement |
JOP20190088A1 (ar) | 2016-10-21 | 2019-04-21 | Us Agriculture | نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها |
WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
CA3045315A1 (en) | 2016-11-30 | 2018-06-07 | Boehringer Ingelheim Animal Health USA Inc. | Attenuated swine influenza vaccines and methods of making and use thereof |
GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
CA3047101A1 (en) | 2016-12-14 | 2018-06-21 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them |
EP3391903B1 (en) | 2017-04-21 | 2022-02-23 | The Pirbright Institute | Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens |
EP3675901A1 (en) | 2017-08-31 | 2020-07-08 | Boehringer Ingelheim Animal Health USA Inc. | Streptococcus suis vaccines to protect against reproductive, nursery-age, and growing pig diseases and methods of making and use thereof |
EP3678699A1 (en) | 2017-09-07 | 2020-07-15 | University Of Oslo | Vaccine molecules |
US20220118076A1 (en) | 2017-09-07 | 2022-04-21 | University Of Oslo | Vaccine molecules |
US20200276299A1 (en) | 2017-09-08 | 2020-09-03 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
WO2019173438A1 (en) | 2018-03-06 | 2019-09-12 | Stc. Unm | Compositions and methods for reducing serum triglycerides |
MX2020013553A (es) | 2018-06-12 | 2021-02-26 | Glaxosmithkline Biologicals Sa | Polinucleotidos y polipeptidos de adenovirus. |
MX2021001479A (es) | 2018-08-07 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Novedosos procesos y vacunas. |
WO2020128012A1 (en) | 2018-12-21 | 2020-06-25 | Glaxosmithkline Biologicals Sa | Methods of inducing an immune response |
BR112021013241A2 (pt) | 2019-01-04 | 2021-09-14 | Boehringer Ingelheim Animal Health USA Inc. | Cepas atenuadas de bordetella bronchiseptica, vacinas orais contendo as cepas atenuadas e métodos de preparação e uso das mesmas |
WO2020243115A1 (en) | 2019-05-25 | 2020-12-03 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
WO2021097347A1 (en) | 2019-11-15 | 2021-05-20 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
JP2023503086A (ja) | 2019-11-22 | 2023-01-26 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 細菌サッカリド複合糖質ワクチンの用法及び用量 |
CN117120087A (zh) | 2020-12-23 | 2023-11-24 | 高级健康研究所 | 茄尼醇疫苗助剂及其制备方法 |
WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
WO2022207793A1 (en) | 2021-03-31 | 2022-10-06 | Vib Vzw | Vaccine compositions for trypanosomatids |
WO2023081486A1 (en) | 2021-11-08 | 2023-05-11 | Nurix Therapeutics, Inc. | Toll-like receptor therapy combinations with cbl-b inhibitor compounds |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1234718A (en) | 1914-03-21 | 1917-07-31 | Int Harvester Canada | Buckle. |
ZA695759B (en) * | 1968-09-19 | 1971-03-31 | Merck & Co Inc | Stimulation of antibody response |
US3725545A (en) * | 1971-02-03 | 1973-04-03 | R Maes | Enhancement of antibody production by nucleic acid-polycation complexes |
US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US4849513A (en) | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
US5015733A (en) | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5268365A (en) | 1988-03-11 | 1993-12-07 | Rudolph Frederick B | Nucleotides, nucleosides, and nucleobases in immune function restoration enhancement or maintenance |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
JPH09501936A (ja) | 1993-08-26 | 1997-02-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置 |
US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5780448A (en) * | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
WO1997028259A1 (en) | 1996-01-30 | 1997-08-07 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
JP4111403B2 (ja) | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 免疫刺激ポリヌクレオチド/免疫調節分子複合体 |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
AU7589398A (en) | 1997-05-19 | 1998-12-11 | Merck & Co., Inc. | Oligonucleotide adjuvant |
AU753172B2 (en) | 1997-06-06 | 2002-10-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1872786A1 (en) * | 1997-09-05 | 2008-01-02 | The Regents of the University of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
AU2001249609A1 (en) * | 2000-03-28 | 2001-10-08 | Department Of Veterans Affairs | Methods for increasing a cytotoxic T lymphocyte response in vivo |
-
1997
- 1997-10-09 JP JP51864998A patent/JP4111403B2/ja not_active Expired - Lifetime
- 1997-10-09 CA CA002268825A patent/CA2268825C/en not_active Expired - Lifetime
- 1997-10-09 EP EP05001324A patent/EP1537877A3/en not_active Withdrawn
- 1997-10-09 AT AT97912831T patent/ATE292980T1/de active
- 1997-10-09 US US09/308,036 patent/US6610661B1/en not_active Expired - Lifetime
- 1997-10-09 ES ES97912831T patent/ES2241042T3/es not_active Expired - Lifetime
- 1997-10-09 DE DE69733020T patent/DE69733020T2/de not_active Expired - Lifetime
- 1997-10-09 WO PCT/US1997/019004 patent/WO1998016247A1/en active IP Right Grant
- 1997-10-09 EP EP97912831A patent/EP0930893B1/en not_active Expired - Lifetime
- 1997-10-09 AU AU49921/97A patent/AU4992197A/en not_active Abandoned
-
2003
- 2003-03-20 US US10/394,092 patent/US20030232780A1/en not_active Abandoned
- 2003-03-20 US US10/394,387 patent/US7208478B2/en not_active Expired - Fee Related
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011057699A (ja) * | 2002-08-15 | 2011-03-24 | Three M Innovative Properties Co | 免疫刺激性組成物、および免疫応答の刺激方法 |
JP2006507265A (ja) * | 2002-08-15 | 2006-03-02 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫刺激性組成物、および免疫応答の刺激方法 |
JP4860923B2 (ja) * | 2002-08-15 | 2012-01-25 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫刺激性組成物、および免疫応答の刺激方法 |
JP4850512B2 (ja) * | 2003-05-15 | 2012-01-11 | 独立行政法人科学技術振興機構 | 免疫刺激剤 |
KR100872472B1 (ko) * | 2003-05-15 | 2008-12-05 | 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 | 면역자극제 |
WO2004100965A1 (ja) * | 2003-05-15 | 2004-11-25 | Japan Science And Technology Agency | 免疫刺激剤 |
JPWO2004100965A1 (ja) * | 2003-05-15 | 2006-07-13 | 独立行政法人科学技術振興機構 | 免疫刺激剤 |
WO2010098432A1 (ja) | 2009-02-27 | 2010-09-02 | 東レ株式会社 | 免疫原性組成物 |
US9056095B2 (en) | 2009-02-27 | 2015-06-16 | Toray Industries, Inc. | Immunogenic composition |
WO2012026508A1 (ja) | 2010-08-26 | 2012-03-01 | 東レ株式会社 | 免疫原性組成物 |
US9980913B2 (en) | 2010-08-26 | 2018-05-29 | Toray Industries, Inc. | Immunogenic composition |
WO2015118789A1 (ja) * | 2014-02-06 | 2015-08-13 | 独立行政法人科学技術振興機構 | ペプチド/β-1,3-グルカン複合体及びその製造方法並びにそれを含む医薬組成物 |
EP3103807A4 (en) * | 2014-02-06 | 2017-02-01 | Japan Science And Technology Agency | Peptide/ -1,3-glucan complex and production method therefor, and pharmaceutical composition containing peptide/ -1,3-glucan complex |
JPWO2015118789A1 (ja) * | 2014-02-06 | 2017-03-23 | 国立研究開発法人科学技術振興機構 | ペプチド/β−1,3−グルカン複合体及びその製造方法並びにそれを含む医薬組成物 |
US10195270B2 (en) | 2014-02-06 | 2019-02-05 | Japan Science And Technology Agency | Peptide/β-1,3-glucan complex and production method thereof and pharmaceutical composition containing peptide/β-1,3-glucan complex |
Also Published As
Publication number | Publication date |
---|---|
US20040006010A1 (en) | 2004-01-08 |
WO1998016247A1 (en) | 1998-04-23 |
DE69733020D1 (de) | 2005-05-19 |
JP4111403B2 (ja) | 2008-07-02 |
ATE292980T1 (de) | 2005-04-15 |
CA2268825C (en) | 2006-04-18 |
EP1537877A2 (en) | 2005-06-08 |
US7208478B2 (en) | 2007-04-24 |
EP0930893A1 (en) | 1999-07-28 |
CA2268825A1 (en) | 1998-04-23 |
EP1537877A3 (en) | 2005-08-03 |
DE69733020T2 (de) | 2006-02-16 |
US20030232780A1 (en) | 2003-12-18 |
US6610661B1 (en) | 2003-08-26 |
ES2241042T3 (es) | 2005-10-16 |
AU4992197A (en) | 1998-05-11 |
EP0930893B1 (en) | 2005-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4111403B2 (ja) | 免疫刺激ポリヌクレオチド/免疫調節分子複合体 | |
US7223398B1 (en) | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof | |
AU760304B2 (en) | Immunostimulatory oligonucleotides with modified bases and methods of use thereof | |
JP4663113B2 (ja) | 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用 | |
US7183111B2 (en) | Immunomodulatory formulations and methods for use thereof | |
JP4101888B2 (ja) | 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法 | |
US6589940B1 (en) | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof | |
US20040006034A1 (en) | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof | |
JP2004530629A (ja) | 免疫刺激rna/dnaハイブリッド分子 | |
JP2006505523A (ja) | 免疫調節組成物、その製造方法および使用方法 | |
AU776288B2 (en) | Methods and adjuvants for stimulating mucosal immunity | |
EP1374894A2 (en) | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof | |
AU768178B2 (en) | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates | |
AU2002301218B2 (en) | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041008 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041008 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070522 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070816 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070921 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20071016 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080404 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110418 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110418 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120418 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120418 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130418 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130418 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140418 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |